Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world retrospective study of PD-1 monoclonal antibody in advanced hepatocellular carcinoma
ChiCTR2100047779Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of PD-1 Monoclonal Antibody in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Progression-free survival. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
PD-1 Monoclonal Antibody
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100047779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047779.